Results 101 to 110 of about 3,407,318 (341)

THE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTOR

Klinicist, 2014
The role of P2Y12 receptor blocker clopidogrel after the introduction into clinical practice of new, more powerful and stable operating drugs belonging to this class of antiplatelet agents is discussed.
S. R. Gilyarevsky, A. G. Larin, P. Y. Lopotovsky, I. M. Kuzmina, O. V. Baturina   +4 more
doaj   +3 more sources

Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

Therapeutics and Clinical Risk Management, 2014
Gianmarco Iannopollo,1 Rita Camporotondo,2 Gaetano M De Ferrari,2 Sergio Leonardi2 1Università degli Studi di Pavia, Pavia, 2Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Abstract: Coronary and cerebrovascular atherothrombosis are the ...
Iannopollo G, Camporotondo R, De Ferrari GM, Leonardi S   +3 more
doaj  

Transperineal ultrasound-guided prostate biopsy is safe even when patients are on combination antiplatelet and/or anticoagulation therapy

BMC Urology, 2017
Background To assess whether hemorrhagic complications associated with transperineal prostate biopsy increased in patients on antiplatelet and/or anticoagulant therapy.
Kimitoshi Saito, Satoshi Washino, Yuhki Nakamura, Tsuzumi Konishi, Masashi Ohshima, Yoshiaki Arai, Tomoaki Miyagawa   +6 more
doaj   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

, 2015
Peer reviewedPublisher ...
Counsell, Carl, Kane, Edward J, Sandercock, Peter A G   +2 more
core   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Selective COX-2 inhibitors and risk of myocardial infarction [PDF]

, 2005
Selective inhibitors of cyclooxygenase- 2 ( COX- 2, ` coxibs') are highly effective anti-inflammatory and analgesic drugs that exert their action by preventing the formation of prostanoids.
Klauss, V., Krotz, F., Schiele, T. M., Sohn, Hae-Young   +3 more
core   +1 more source

Electrochemical Three‐Component Synthesis of Vinyl Sulfonamides via Decarboxylative Sulfonylation of Cinnamic Acids

ChemSusChem, EarlyView.
An efficient, metal‐free electrochemical three‐component reaction of cinnamic acids, SO2, and amines to access (E)‐β‐styryl sulfonamides is reported. Utilizing graphite electrodes and SO2 stock solutions, this decarboxylative protocol proceeds under mild conditions with high regio‐ and stereoselectivity.
Po‐Chung Chien, Harald Kelm, Georg Manolikakes   +2 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT

Рациональная фармакотерапия в кардиологии, 2018
Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test their knowledge of the basic provisions of the current recommendations on antiplatelet therapy.Material and methods.
N. В. Perepech, A. V. Tregubov
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources